Amgen Aktie
287,40USD | -0,41USD | -0,14% |
WKN: 867900 / ISIN: US0311621009
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 99,74 |
Vanguard Group, Inc. (Subfiler) | 9,28 |
The Vanguard Group, Inc. | 9,13 |
SSgA Funds Management, Inc. | 5,50 |
State Street Corp. | 5,46 |
Vanguard Total Stock Market ETF | 3,17 |
BlackRock Fund Advisors | 3,07 |
PRIMECAP Management Co. | 2,65 |
Vanguard 500 Index Fund | 2,62 |
Geode Capital Management LLC | 2,26 |
BlackRock Institutional Trust Co. NA | 2,21 |
Charles Schwab Investment Management, Inc. | 1,96 |
Invesco QQQ Trust | 1,94 |
Vanguard PRIMECAP Fund | 1,67 |
Capital Research & Management Co. (International Investors) | 1,62 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 23 400 | 24 300 | 24 200 | 25 200 | 26 700 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,99 | 1,04 | 1,07 | 1,04 | 1,05 |
Bilanz (in Mio. USD) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 18 440 | 21 144 | 19 385 | 22 186 | 30 332 |
Summe Anlagevermögen | 41 267 | 41 804 | 41 780 | 42 935 | 66 822 |
Summe Aktiva | 59 707 | 62 948 | 61 165 | 65 121 | 97 154 |
Bilanz (in Mio. USD) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 30 431 | 33 445 | 33 979 | 39 640 | 65 423 |
Summe Fremdkapital | 50 034 | 53 539 | 54 465 | 61 460 | 90 922 |
Summe Eigenkapital | 9 673 | 9 409 | 6 700 | 3 661 | 6 232 |
Summe Passiva | 59 707 | 62 948 | 61 165 | 65 121 | 97 154 |
Adresse
One Amgen Center Drive, 91320-1799 Thousand Oaks | |
Telefon | +1 (805) 447-1000 |
Fax | +1 (805) 447-1010 |
Internet | http://www.amgen.com |
Management
Amy E. Miles
Independent Director |
Brian J. Druker
Independent Director |
Charles M. Holley
Independent Director |
Darryl Sleep
Chief Medical Officer & Senior VP-Global Medical |
David M. Reese
Chief Technology Officer & Executive VP |
Derek Miller
Chief Human Resources Officer |
Ellen Jamison Kullman
Independent Director |
Esteban Santos
Executive Vice President-Operations |
Greg C. Garland
Independent Director |
James E. Bradner
Chief Scientific Officer |
Jean-Charles Soria
SVP-Research and Development |
Jonathan P. Graham
Secretary, Executive VP & General Counsel |
Li Yang
Scientific Director |
Linda H. Louie
Chief Accounting Officer & Vice President-Finance |
Linda H. Louie
Vice President-Finance |
Lori A. Johnston
Executive Vice President |
Mark J. Taisey
Senior VP-Global Regulatory Affairs & Strategy |
Mary Earley Klotman
Director |
Matthew C. Busch
Chief Accounting Officer & Vice President-Finance |
Michael V. Drake
Independent Director |
Mike Zahigian
Chief Information Officer & Senior Vice President |
Murdo J. Gordon
EVP-Global Commercial Operations |
Nancy A. Grygiel
Chief Compliance Officer |
Omar Syed Ishrak
Independent Director |
Paul Burton
Chief Medical Officer |
Peter H. Griffith
Chief Financial Officer & Executive Vice President |
Rachna Khosla
Senior Vice President-Business Development |
Robert A. Bradway
Chairman, President & Chief Executive Officer |
Robert A. Eckert
Lead Independent Director |
Robert T. Fremeau
Scientific Director |
Susan Sweeney
Senior VP-Global Marketing, Access & Capabilities |
Tyler E. Jacks
Independent Director |
Victoria H. Blatter
Senior Vice President-Global Government Affairs |
Wanda M. Austin
Independent Director |